Multi-stakeholder collaborations & biomarker development and implementation

The rise of genomic technologies and increasing interest in personalized medicine have triggered a renewed focus on the role of biomarkers in drug development and clinical care. While many stakeholders, including industry, regulatory agencies, patients, academia, and payers, are involved in biomarker development and use, these stakeholders reside in functional siloes that lead to fragmented outputs and efforts. Thus, although biomarker discovery is extensive, biomarker adoption in the R&D process and clinical care is slow, complex, and opaque. The gap between discovery and practice needs to be bridged by clear and consistent evidentiary standards, regulations and policies. Biomarker adoption requires a systems effort that includes active dialogue and understanding among all stakeholders. The level of discussions and resources (data, samples, expertise, financial, etc.) needed also makes this field particularly fertile for collaboration. This thesis suggests that multi-stakeholder collaborations (MSCs) can address the challenges of biomarker adoption. It describes what has been achieved in existing prominent MSCs, extracts general lessons on their contributions, and provides recommendations on the use of MSCs in drug development. Specifically, MSCs have demonstrated impact across 4 key areas: 1) data generation and establishment of standards; 2) development of scientific processes for biomarker evaluation and use; 3) the structuring of innovative operational and organizational scaffolds for collaboration; and 4) delivery of vetted regulatory recommendations and robust biomarkers for use by drug developers and clinicians. Understanding the roles, evolution, and challenges of MSCs will be important in enhancing the capacity to collaborate to address the complex challenges for biomedical innovation and healthcare outcomes. Thesis Supervisor: Dr. Kenneth A. Oye Title: Associate Professor of Political Science and Engineering Systems Division Thesis Supervisor: Gigi Hirsch Title: Executive Director of the MIT Center for Biomedical Innovation Thesis Supervisor: Magdalini Papadaki Title: Research Scientist of the of the MIT Center for Biomedical Innovation

[1]  J. Woodcock Assessing the Clinical Utility of Diagnostics Used in Drug Therapy , 2010, Clinical pharmacology and therapeutics.

[2]  B. Evans Establishing Clinical Utility of Pharmacogenetic Tests in the Post‐FDAAA Era , 2010, Clinical pharmacology and therapeutics.

[3]  F. Frueh,et al.  Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer , 2014, Clinical Cancer Research.

[4]  Richard Pazdur,et al.  Pathological complete response and accelerated drug approval in early breast cancer. , 2012, The New England journal of medicine.

[5]  D. Berry,et al.  I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.

[6]  A Model for Accelerating Identification and Regulatory Approval of Effective Investigational Agents , 2012 .

[7]  Alisa Opar Bridging the drug—diagnostic divide , 2011, Nature Reviews Drug Discovery.

[8]  Janet Woodcock,et al.  Accelerating identification and regulatory approval of investigational cancer drugs. , 2011, JAMA.

[9]  E. Berndt,et al.  Economic challenges and possible policy actions to advance stratified medicine. , 2012, Personalized medicine.

[10]  C. Sigman,et al.  Cancer biomarkers: selecting the right drug for the right patient , 2012, Nature Reviews Drug Discovery.

[11]  A. Chinnaiyan,et al.  Systematic, evidence-based discovery of biomarkers at the NCI , 2012, Clinical & Experimental Metastasis.

[12]  Steven Gutman,et al.  Opinion: The US Food and Drug Administration perspective on cancer biomarker development , 2006, Nature Reviews Cancer.

[13]  G. Rasi,et al.  Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union , 2014, Clinical Cancer Research.

[14]  Krishna Prasad,et al.  Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium , 2010, Nature Biotechnology.

[15]  Master Protocol for squamous cell lung cancer readies for launch , 2014, Nature Biotechnology.

[16]  D Amakye,et al.  A Prototypical Process for Creating Evidentiary Standards for Biomarkers and Diagnostics , 2008, Clinical pharmacology and therapeutics.

[17]  F. Frueh,et al.  Biomarker qualification pilot process at the US Food and Drug Administration , 2007, The AAPS Journal.

[18]  Nola Hylton,et al.  Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  E. Mansfield,et al.  FDA Perspective on Companion Diagnostics: An Evolving Paradigm , 2014, Clinical Cancer Research.

[20]  Frank D Sistare,et al.  Research at the interface of industry, academia and regulatory science , 2010, Nature Biotechnology.

[21]  Efthymios Manolis,et al.  New pathway for qualification of novel methodologies in the European medicines agency , 2011, Proteomics. Clinical applications.

[22]  F. Goodsaid,et al.  Translational Medicine and the Value of Biomarker Qualification , 2010, Science Translational Medicine.

[23]  A. Szarfman,et al.  Qualification of cardiac troponins for nonclinical use: a regulatory perspective. , 2013, Regulatory toxicology and pharmacology : RTP.

[24]  C. Compton,et al.  Public-private partnerships as driving forces in the quest for innovative medicines , 2013, Clinical and Translational Medicine.

[25]  Jiri Aubrecht,et al.  Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact , 2010, Nature Reviews Drug Discovery.

[26]  James H. Doroshow,et al.  AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development , 2010, Clinical Cancer Research.

[27]  Staffan Jacobsson,et al.  Innovation systems: analytical and methodological issues , 2002 .

[28]  S. McCune,et al.  The Critical Path Initiative: Leveraging Collaborations to Enhance Regulatory Science , 2012, Clinical pharmacology and therapeutics.

[29]  Kristen Anton,et al.  Bioinformatics: biomarkers of early detection. , 2010, Cancer biomarkers : section A of Disease markers.

[30]  George Poste,et al.  Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. , 2012, Trends in molecular medicine.

[31]  R. Hockett,et al.  Regulation of Laboratory‐Developed Tests: The Case for Utilizing Professional Associations , 2010, Clinical pharmacology and therapeutics.

[32]  Federico M Goodsaid,et al.  Strategic paths for biomarker qualification. , 2008, Toxicology.

[33]  J. Bonventre,et al.  Biomarkers : in medicine, drug discovery, and environmental health , 2010 .

[34]  Federico Goodsaid,et al.  Evolution of biomarker qualification at the health authorities , 2010, Nature Biotechnology.

[35]  Sujoy Ghosh,et al.  The Biomarkers Consortium: Practice and Pitfalls of Open‐Source Precompetitive Collaboration , 2010, Clinical pharmacology and therapeutics.

[36]  Leslie M. Shaw,et al.  Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium , 2013, Alzheimer's & Dementia.

[37]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[38]  S. Amur,et al.  The Experience with Voluntary Genomic Data Submissions at the FDA and a Vision for the Future of the Voluntary Data Submission Program , 2007, Clinical pharmacology and therapeutics.

[39]  Gene A Pennello,et al.  Analytical and clinical evaluation of biomarkers assays: When are biomarkers ready for prime time? , 2013, Clinical trials.

[40]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[41]  E. Gillanders,et al.  Translational Research in Cancer Genetics: The Road Less Traveled , 2009, Public Health Genomics.

[42]  Asher Mullard,et al.  2013 FDA drug approvals , 2014, Nature Reviews Drug Discovery.

[43]  Malorye Allison Biomarker-led adaptive trial blazes a trail in breast cancer , 2010, Nature Biotechnology.

[44]  Greg Miller,et al.  Alzheimer's biomarker initiative hits its stride. , 2009, Science.

[45]  Jiri Aubrecht,et al.  The current status of biomarkers for predicting toxicity , 2013, Expert opinion on drug metabolism & toxicology.

[46]  K. Coombes,et al.  What information should be required to support clinical "omics" publications? , 2011, Clinical chemistry.

[47]  J. Wagner,et al.  Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.

[48]  Bradley L. Smith,et al.  Development of Targeted Agents and Companion Diagnostics , 2012 .

[49]  Evolving Global Regulatory Science Through the Voluntary Submission of Data , 2014, Therapeutic innovation & regulatory science.

[50]  E. Berndt,et al.  Uncertain prognosis for high-quality diagnostics: clinical challenges, economic barriers and needed reforms. , 2013, Pharmacogenomics.

[51]  F. Frueh,et al.  REVIEWTHEME : GENERAL Integration and use of biomarkers in drug development , regulation and clinical practice : a US regulatory perspective , 2008 .

[52]  F. Frueh,et al.  Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop , 2006, The Pharmacogenomics Journal.

[53]  I. Zineh,et al.  Pharmacogenetics in medicine: barriers, critical factors and a framework for dialogue. , 2009, Personalized medicine.

[54]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[55]  Competitors try collaboration to speed drug development. , 2010, Journal of the National Cancer Institute.

[56]  Sudhir Srivastava,et al.  The early detection research network: 10-year outlook. , 2013, Clinical chemistry.

[57]  H. Etzkowitz,et al.  Triple Helix Systems: An Analytical Framework for Innovation Policy and Practice in the Knowledge Society , 2013 .

[58]  Joel Cutcher-Gershenfeld,et al.  Precompetitive consortia in biomedicine—how are we doing? , 2013, Nature Biotechnology.

[59]  Ohid Yaqub,et al.  Public-private collaborations and partnerships in stratified medicine: making sense of new interactions. , 2012, New biotechnology.

[60]  Christine M. Micheel,et al.  Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .

[61]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[62]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[63]  Rajiv Mahajan,et al.  Food and drug administration’s critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies , 2010, Journal of pharmacy & bioallied sciences.

[64]  S. Ghosh,et al.  Utility of Adiponectin as a Biomarker Predictive of Glycemic Efficacy Is Demonstrated by Collaborative Pooling of Data From Clinical Trials Conducted by Multiple Sponsors , 2009, Clinical pharmacology and therapeutics.

[65]  K. Romero,et al.  The Coalition Against Major Diseases: Developing Tools for an Integrated Drug Development Process for Alzheimer's and Parkinson's Diseases , 2009, Clinical pharmacology and therapeutics.

[66]  Z. Khachaturian Perspective on the Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.

[67]  Frank D Sistare,et al.  Towards consensus practices to qualify safety biomarkers for use in early drug development , 2010, Nature Biotechnology.

[68]  S. Teutsch,et al.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group , 2009, Genetics in Medicine.

[69]  E. Drucker,et al.  Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine , 2013, EPMA Journal.

[70]  Marc S. Williams,et al.  The EGAPP initiative: lessons learned , 2013, Genetics in Medicine.

[71]  L. Lesko,et al.  Paving the Critical Path: How can Clinical Pharmacology Help Achieve the Vision? , 2007, Clinical pharmacology and therapeutics.

[72]  M. Goldman,et al.  The Innovative Medicines Initiative: A European Response to the Innovation Challenge , 2012, Clinical pharmacology and therapeutics.

[73]  M. Day,et al.  Translational medicine--a paradigm shift in modern drug discovery and development: the role of biomarkers. , 2009, Advances in experimental medicine and biology.

[74]  I. Zineh,et al.  Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. , 2011, Expert opinion on medical diagnostics.

[75]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[76]  Asher Mullard,et al.  Multicompany trials adapt to disciplines beyond cancer , 2014, Nature Medicine.

[77]  Eslie Dennis,et al.  Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium , 2013 .

[78]  Adrian Burton,et al.  Big science for a big problem: ADNI enters its second phase , 2011, The Lancet Neurology.

[79]  B. Quinn Payers and the Assessment of Clinical Utility for Companion Diagnostics , 2010, Clinical pharmacology and therapeutics.

[80]  D. Carbone,et al.  Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development , 2012, Clinical Cancer Research.

[81]  P. Aisen Q & A: The Alzheimer's disease neuroimaging initiative , 2011, BMC medicine.

[82]  L. Lesko,et al.  Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.

[83]  Federico Goodsaid,et al.  Process map proposal for the validation of genomic biomarkers. , 2006, Pharmacogenomics.

[84]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[85]  J. Wagner Strategic approach to fit-for-purpose biomarkers in drug development. , 2008, Annual review of pharmacology and toxicology.

[86]  B. Conley,et al.  Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use , 2012, Clinical Cancer Research.

[87]  Impact of discrepant results from clinical laboratories on patients and pharmaceutical trials: evidence from proficiency testing results. , 2009, Biomarkers in medicine.

[88]  Krishna Kodukula,et al.  Biomarkers in pharmacology and drug discovery. , 2014, Biochemical pharmacology.

[89]  Andrea C. Rinaldi,et al.  Teaming up for biomarker future , 2011, EMBO reports.

[90]  A. Senderowicz,et al.  Similarities and Differences in the Oncology Drug Approval Process between FDA and European Union with Emphasis on In Vitro Companion Diagnostics , 2014, Clinical Cancer Research.

[91]  J. Bozell Breaking the vicious cycle. , 2007, Mental health today.

[92]  H. Zwierzina,et al.  Biomarkers in drug development. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  Weida Tong,et al.  FDA-approved drug labeling for the study of drug-induced liver injury. , 2011, Drug discovery today.

[94]  Ronald L Weiss,et al.  The long and winding regulatory road for laboratory-developed tests. , 2012, American journal of clinical pathology.

[95]  Abdel-Baset Halim,et al.  Biomarkers in Drug Development: A Useful Tool but Discrepant Results May Have a Major Impact , 2011 .

[96]  P. Wagner,et al.  New paradigms in translational science research in cancer biomarkers. , 2012, Translational research : the journal of laboratory and clinical medicine.

[97]  F. Dieterle,et al.  Promises of Biomarkers in Drug Development – A Reality Check , 2007, Chemical biology & drug design.